Holy Stone Healthcare’s new drug, CA102N, for the treatment of colorectal cancer is conducting phase I clinical trials in the US on patients with late-stage chemo-refractory mCRC. The company applied to the US FDA on November 24, 2021, for compassionate use and expanded access for the patient. The application was approved on December 21, 2021.